Novo, Ascendis to work on monthly GLP-1; KalVista makes a royalty deal

Plus, news about Disc Medicine, OSE Immunotherapeutics, CrossBridge Bio, Lomond Therapeutics, Relief Therapeutics and Renexxion: Novo Nordisk, Ascendis Pharma ink deal: The Danish drugmaker will pay up to $285 million as ...